Skip to content

Psilocybin research published in 2025

Page 17 of 27: studies 321 to 340 of 530, newest first. Back to the psilocybin overview

Studies

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

Psychedelic Medicine May 16, 2025 Roland R. Griffiths, William A. Richards, Robert L. Jesse et al. 14 citations

Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy....

Tū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms

Journal of Psychedelic Studies May 16, 2025 Anna-Leigh Hodge, Anna Forsyth, Tehseen Noorani et al. 6 citations

Abstract Psilocybin, a naturally occurring psychedelic compound found in certain fungi has long been used by Indigenous cultures within ritual and ceremony for healing and spiritual purposes (Spiers et al., 2024). While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted...

Pathway engineering for the biosynthesis of psychedelics

Current Opinion in Biotechnology May 15, 2025 Zachary N. Abrahms, Abhishek K. Sen, J. Andrew Jones 2 citations

Naturally occurring psychoactive compounds have been used for cultural and ethnomedical purposes for centuries. Several more such molecules continue to be chemically synthesized, exhibiting a wide range of potency, therapeutic, and hallucinogenic effects. Promising clinical data and a renewed interest in understanding the cellular mechanisms of action have inspired synthetic biology efforts to...

Music and non-music approaches in psilocybin-assisted psychotherapy: The sound of silence

Journal of Psychedelic Studies May 15, 2025 Sara G. Gloeckler, Julien Thibault Lévesque, Alexandre Lehmann et al. 3 citations

Abstract Music is integral to Psilocybin-assisted psychotherapy (PAP), believed to enhance therapeutic outcomes by structuring experiences and facilitating emotional expression. However, the effects of conducting PAP without music are underexplored. This study examines the experiences of two breast cancer patients undergoing psilocybin therapy under Canada's compassionate access program,...

The Intersection of Psychedelics and Sleep: Exploring the Impacts on Sleep Architecture, Dream States, and Therapeutic Implications

ACS Pharmacology & Translational Science May 15, 2025 Haojiang Zhai, Hongshuang Wang, Haohong Li et al. 3 citations

The interplay between psychedelics, such as psilocybin, lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT), and sleep is an emerging area, but their impact on sleep remains relatively underexplored. This viewpoint provides a perspective on how psychedelics may alter sleep phases, dreaming, and their potential therapeutic applications for sleep disorders.

DOI: 10.1021/acsptsci.5c00234 (opens in new tab) Psilocybin Insomnia Psychedelics Profoundly impact +7

Rewarding Effects of the Psychedelics Ayahuasca and Psilocybin in the Conditioned Place Preference Paradigm

Digital Library of Theses and Dissertations (Universidade de São Paulo) May 12, 2025 Vítor Bruno

A presente tese foi dividia em dois capítulos. Capítulo I. Esse capítulo tem como objetivo investigar o possível potencial de reforço induzido pela ayahuasca por meio do paradigma de preferência condicionada por lugar (conditioned place preference, CPP), bem como avaliar se a ayahuasca é capaz de modular a CPP induzida pela cocaína durante as fases de aquisição, expressão e reinstalação da CPP...

Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review

Journal of Psychopharmacology May 12, 2025 Clémentine Estric, Thomas Duron, Sarah Kabani et al. 10 citations

Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a psychedelic (setting) are not standardized. We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, articles were identified in the PubMed and Web of Science databases...

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review

Psychiatry Research May 8, 2025 Noah Chisamore, Lee Phan, Roger S McIntyre et al. 7 citations

Psychedelics have re-emerged as promising treatments for mood disorders. The current model provides a moderate-to-high dose of a psychedelic agent (e.g., psilocybin) to reliably induce an altered state of consciousness. Unfortunately, the hallucinatory effects limit the treatment's potential scalability given patients' vulnerability and extensive monitoring costs, leading to growing interest in...

Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders.

ACS Chemical Neuroscience May 7, 2025 Hongshuang Wang, Xiaohui Wang 5 citations

This viewpoint explores the therapeutic potential of psychedelics in treating neuropsychiatric disorders, particularly through the modulation of brain entropy and the experience of ego dissolution. Psychedelics disrupt rigid neural patterns, facilitating enhanced connectivity and fostering profound emotional breakthroughs that may alleviate symptoms of disorders like depression, anxiety, PTSD,...

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

American Journal of Psychiatry May 7, 2025 Matthew B. Wall, Lysia Demetriou, Bruna Giribaldi et al. 16 citations

Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. These results are consistent with prior findings that the antidepressant action of SSRIs is often accompanied by a reduction in emotional responsiveness, but this effect may not occur in psychedelic therapy.

DOI: 10.1176/appi.ajp.20230751 (opens in new tab) Full text (opens in new tab) Psilocybin Cognitive neuroscience Depressive disorders Psychopharmacology +7

Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder

PLoS One May 7, 2025 Grant Jones 2 citations

Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association. Objective: To assess the...

Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats

Research Square May 6, 2025 Zitong Wang, Brett Robbins, Ryan Zhuang et al. preprint

Abstract Major depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepressant trials, approximately one-third of MDD patients remain symptomatic, progressing to treatment-resistant depression (TRD). This persistence possibly is due to the multifaceted etiology of TRD, encompassing biological, psychological, and...

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.

American Journal of Psychotherapy May 6, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al. 7 citations

Psychedelic therapies are promising new treatment options in psychiatry. Including the use of physical touch as part of treatment is an area of debate. This study aimed to characterize the viewpoints of practitioners on the use of touch in psychedelic therapy. An anonymous survey was distributed via e-mail to the contacts listed on ClinicalTrials.gov for trials of psilocybin and lysergic acid...

A landscape analysis of psychedelic retreat organizations advertising online

PLoS One May 2, 2025 Nikita Singh, Srijith Kambala, Logan Neitzke-Spruill et al. 10 citations

Research into psychedelics’ clinical potential has corresponded to a growth in public interest and adult use. One common pathway to accessing psychedelics is through psychedelic retreats. While individual retreats have been characterized in the anthropological literature, no systematic evaluation of the psychedelic retreat industry exists. Assessing the characteristics of the psychedelic...

Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series

Cephalalgia Reports May 1, 2025 Jonathan A. Leighton, Chieh Grace Lau, Aisha Savdo et al. 2 citations

Background Cluster headache is an excruciating condition for which standard treatments are usually insufficient. Evidence has accumulated that serotonergic psychedelic indoleamines including psilocybin and LSD can be effective in preventing attacks. Methods In this case series, nine patients with episodic and chronic cluster headache that didn’t respond to conventional treatments were treated...

Psilocybin

May 1, 2025 Jessi Humphreys, Lou Lukas, Yvan Beaussant et al.

Abstract Psilocybin, a naturally occurring psychoactive compound found in more than 200 mushroom species, has an enduring history of use in sacred rituals of Indigenous healers worldwide. With selective serotonin receptor binding, activation of the serotonergic neurological system enables psilocybin to potentiate neuroplasticity, enabling individuals to engage in meaning-making from psychedelic...

Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.

European journal of anaesthesiology May 1, 2025 Mansi Dave, Ron Shore, Tracy Cupido et al.

Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As exploratory studies demonstrate clinical efficacy with few adverse events, it is expected that more patients will ingest psychedelic drugs. For therapeutic reasons, as with any drug, anaesthesiologists must be aware of its physiological effects and...

DOI: 10.1097/eja.0000000000002138 (opens in new tab) Full text (opens in new tab) Drug interactions Psychedelic medicine Anesthesia safety Surgical protocols +1

The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.

Neuroscience & Biobehavioral Reviews May 1, 2025 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al. 36 citations

Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intensity and quality of psychedelic experiences plays a significant role in mediating therapeutic effects. However, the strength of this association across diagnoses and treatment settings remains underexplored. We searched MEDLINE, Embase, and PsycINFO...

Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.

Drug safety May 1, 2025 Ahmed Al-Imam, Riccardo Lora, Marek A Motyka et al. 1 citation

Psychedelics are gaining attention for their therapeutic potential in modern and personalized medicine. Online forums such as Erowid provide valuable user insights, but analyses of these experiences using natural language processing (NLP) remain scarce. This study aims to utilize NLP, including sentiment and lexicon analysis, to examine user-generated experience reports on psilocybin-containing...

DOI: 10.1007/s40264-025-01530-z (opens in new tab) Full text (opens in new tab) Consciousness research Altered states Psychedelics Drug effects